Summary by Futu AI
WUXI BIO announced the company structure and governance status from January 1 to December 31, 2024. The company Holds 100% of the shares in WUXI VACCINE (CAYMAN) LIMITED and part of the shares in WUXI XDC (CAYMAN) LIMITED, which is listed on the Hong Kong Stock Exchange. The company uses RMB as its functional currency, while USD is utilized for international Business operations.The company has established a remuneration committee and a strategic committee, and has developed securities trading guidelines for Directors. In addition, the company has implemented a Restricted Share Reward Plan, which was adopted on January 15, 2018, and amended on June 27, 2023, with an authorized limit of 254,904,706 shares.In terms of related parties, the company is associated with WUXI APPTEC (CAYMAN) LIMITED, which was delisted from NYSE on December 10, 2015, and the current Director, Cao Yanling, serves in both companies. The company also maintains Business connections with WUXI APPTEC (listed on Hong Kong Stock Exchange and Shanghai Stock Exchange) and operates in multiple jurisdictions, including China and the USA.
